Microvitality
- Biotech or pharma, animal health
- Biotech or pharma, therapeutic R&D
- Medical device or technology
- Diagnostics
Microvitality is advancing gut health diagnostics with a novel ingestible sampling capsule providing unprecedented access to the small intestine. Starting with SIBO (Small Intestine Bacterial Overgrowth), the most underdiagnosed gastrointestinal disease affecting an estimated 1.8 billion people globally, we aim to expand to related conditions such as IBS, currently, the most expensive diagnosis in gastroenterology. Microvitality’s capsule has been under development over the last 8 years at Tufts University and has demonstrated robust performance in pre-clinical studies, with a first-in-human study set to commence in 2025. We are raising a pre-seed round of $1M to evaluate safety and feasibility in healthy and diseased patients, finalize outsourced product manufacturing, and initiate investigational study partnerships.
Address
BostonMassachusetts
United States
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}